Inflammasense
InflammaSense is a San Diego-based medical device company developing novel wearable and point-of-care diagnostic technologies for the early detection of sepsis and inflammatory diseases. The company's flagship product, the VITAL-X-PATCH, records a new vital sign — Autonomic Neurography (ANG) — and transmits disease severity data to clinicians with millisecond precision. Paired with the Handheld Ultrasensitive Bioassay Sensor (HUBS), a point-of-care miRNA diagnostic system, the platform enables continuous, real-time stratification of autonomic and inflammation states using proprietary machine-learning algorithms. Founded by Dr. Imanuel Lerman (CEO) and Rahul Singh (CTO), the company holds multiple patents with licensing from UCSD and Duke University, and is backed by $5.7 million in combined dilutive and non-dilutive funding from investors including KittyHawk Ventures and government agencies including BARDA, DARPA/ARPA-H, and NIH.